{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:21:10Z","timestamp":1787667670857,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.chest.2020.11.060","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T01:17:50Z","timestamp":1608081470000},"page":"1734-1746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice"],"prefix":"10.1016","volume":"159","author":[{"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanisha D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Ariely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice T.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi L.","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Thomason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Reynold A.","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2020.11.060_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.060_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the severe asthma research program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2020.11.060_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-014-0213-9","article-title":"Defining phenotypes in asthma: a step towards personalized medicine","volume":"74","author":"Chung","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.chest.2020.11.060_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","article-title":"High blood eosinophil count is associated with more frequent asthma attacks in asthma patients","volume":"113","author":"Tran","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.chest.2020.11.060_bib5","first-page":"A4235","article-title":"Elevated blood eosinophil level is a risk factor for exacerbations in adult persistent asthma","volume":"189","author":"Zeiger","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2020.11.060_bib7","first-page":"7","article-title":"Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma","volume":"7","author":"Walsh","year":"2013","journal-title":"Biologics"},{"issue":"5","key":"10.1016\/j.chest.2020.11.060_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2020.11.060_bib10","doi-asserted-by":"crossref","first-page":"1901511","DOI":"10.1183\/13993003.01511-2019","article-title":"The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: endorsed by the International Primary care Respiratory Group and the World Allergy Organization","volume":"54","author":"Roche","year":"2019","journal-title":"Eur Resp J"},{"issue":"1","key":"10.1016\/j.chest.2020.11.060_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1183\/20734735.015414","article-title":"Real-world research and its importance in respiratory medicine","volume":"11","author":"Price","year":"2015","journal-title":"Breathe (Sheff)"},{"issue":"4","key":"10.1016\/j.chest.2020.11.060_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.060_bib13","first-page":"S18","article-title":"Appropriate use of oral corticosteroids for severe asthma","volume":"209","author":"Ramsahai","year":"2018","journal-title":"Med J Aust"},{"issue":"10","key":"10.1016\/j.chest.2020.11.060_bib14","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.147.10.3490","article-title":"Glucocorticoids inhibit cytokine-mediated eosinophil survival","volume":"147","author":"Wallen","year":"1991","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.chest.2020.11.060_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.chest.2020.11.060_bib16","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.chest.2020.11.060_bib17","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.anai.2017.08.275","article-title":"P237 real world effects of reslizumab: a retrospective chart review","volume":"119","author":"Crowther","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.chest.2020.11.060_bib18","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.98.12061322","article-title":"Costs of asthma according to the degree of severity","volume":"12","author":"Serra-Batlles","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.11.060_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"Godard","year":"2002","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.11.060_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40413-018-0205-4","article-title":"Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis","volume":"11","author":"Fl\u00f3rez-Tanus","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"7","key":"10.1016\/j.chest.2020.11.060_bib21","first-page":"848","article-title":"Economic burden of illness among patients with severe asthma in a managed care setting","volume":"22","author":"Chastek","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220354507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220354507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:01:20Z","timestamp":1762124480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220354507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0012369220354507"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.11.060","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.11.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}